2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary

Bernard J. Gersh; Barry J. Maron; Robert O. Bonow; Joseph A. Dearani; Michael A. Fifer; Mark S. Link; Srihari S. Naidu; Rick A. Nishimura; Steve R. Ommen; Harry Rakowski; Christine E. Seidman; Jeffrey A. Towbin; James E. Udelson; Clyde W. Yancy; Alice K. Jacobs; Sidney C. Smith; Jeffrey L. Anderson; Nancy M. Albert; Christopher E. Buller; Mark A. Creager; Steven M. Ettinger; Robert A. Guyton; Jonathan L. Halperin; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; E. Magnus Ohman; Richard L. Page; William G. Stevenson; Lynn G. Tarkington

doi:10.1016/j.jtcvs.2011.10.019

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary

Bernard J. Gersh, Barry J. Maron, Robert O. Bonow, Joseph A. Dearani, Michael A. Fifer, Mark S. Link, Srihari S. Naidu, Rick A. Nishimura, Steve R. Ommen, Harry Rakowski, Christine E. Seidman, Jeffrey A. Towbin, James E. Udelson, Clyde W. Yancy, Alice K. Jacobs, Sidney C. Smith, Jeffrey L. Anderson, Nancy M. Albert, Christopher E. Buller, Mark A. CreagerSteven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Harlan M. Krumholz, Frederick G. Kushner, E. Magnus Ohman, Richard L. Page, William G. Stevenson, Lynn G. Tarkington

Research output: Contribution to journal › Article › peer-review

109 Scopus citations

Original language	English (US)
Pages (from-to)	1303-1338
Number of pages	36
Journal	Journal of Thoracic and Cardiovascular Surgery
Volume	142
Issue number	6
DOIs	https://doi.org/10.1016/j.jtcvs.2011.10.019
State	Published - Dec 2011

All Science Journal Classification (ASJC) codes

Surgery
Pulmonary and Respiratory Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jtcvs.2011.10.019

Cite this

Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., Seidman, C. E., Towbin, J. A., Udelson, J. E., Yancy, C. W., Jacobs, A. K., Smith, S. C., Anderson, J. L., Albert, N. M., Buller, C. E., ... Tarkington, L. G. (2011). 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. Journal of Thoracic and Cardiovascular Surgery, 142(6), 1303-1338. https://doi.org/10.1016/j.jtcvs.2011.10.019

@article{768bfcdd94d14ec28f6ebde7d6c88057,

title = "2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary",

author = "Gersh, {Bernard J.} and Maron, {Barry J.} and Bonow, {Robert O.} and Dearani, {Joseph A.} and Fifer, {Michael A.} and Link, {Mark S.} and Naidu, {Srihari S.} and Nishimura, {Rick A.} and Ommen, {Steve R.} and Harry Rakowski and Seidman, {Christine E.} and Towbin, {Jeffrey A.} and Udelson, {James E.} and Yancy, {Clyde W.} and Jacobs, {Alice K.} and Smith, {Sidney C.} and Anderson, {Jeffrey L.} and Albert, {Nancy M.} and Buller, {Christopher E.} and Creager, {Mark A.} and Ettinger, {Steven M.} and Guyton, {Robert A.} and Halperin, {Jonathan L.} and Hochman, {Judith S.} and Krumholz, {Harlan M.} and Kushner, {Frederick G.} and Ohman, {E. Magnus} and Page, {Richard L.} and Stevenson, {William G.} and Tarkington, {Lynn G.}",

note = "Funding Information: MMC4 Appendix 1. Appendix 1 Author relationships with industry and other entities (relevant)—2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy Committee member Employer/title Consultant Speaker's bureau Ownership/ partnership/ principal Personal research Institutional, organizational, or other financial benefit Expert witness Voting recusals by section number ∗ Bernard J. Gersh, Co-Chair Mayo Clinic—Professor of Medicine • Abbott Laboratories † • AstraZeneca • Boston Scientific • Bristol-Myers Squibb None None • Amorcyte (DSMB) • CV Therapeutics None 6.2.2.6 6.2.3 6.3.2 6.3.2.4 Barry J. Maron, Co-Chair Minneapolis Heart Institute Foundation—Director, Hypertrophic Cardiomyopathy Center • GeneDx ‡ None None • Medtronic ‡ None None 5.1 6.3.2 6.3.2.4 Robert O. Bonow Northwestern University Feinberg School of Medicine—Goldberg Distinguished Professor of Medicine; Chief, Division of Cardiology None None None None None None None Joseph A. Dearani Mayo Clinic—Professor of Surgery None None None None None None None Michael A. Fifer Massachusetts General Hospital—Director, Hypertrophic Cardiomyopathy Program None None None • Merck ‡ None None 6.2.1 Mark S. Link Tufts Medical Center—Professor of Medicine None • Medtronic • Guidant None • Guidant None • Plaintiff, wrongful death secondary electrocution, 2007–2009 • Defendant, postoperative valve replacement management, 2007–2010 6.2.2.6 6.3.2 6.3.2.4 Srihari S. Naidu Winthrop University Hospital—Director, Cardiac Catheterization Laboratory; Director, Hypertrophic Cardiomyopathy Center None • Abbott Vascular • Cordis • Medtronic None None None None 6.2.2.6 6.3.2 6.3.2.4 Rick A. Nishimura Mayo Clinic—Consultant in Cardiology None None None None None None None Steve R. Ommen Mayo Clinic—Professor of Medicine None None None None None None None Harry Rakowski Toronto General Hospital, University Health Network—Director, Hypertrophic Cardiomyopathy Center; Wigle Chair for HCM Research; Professor of Medicine, University of Toronto None None None • Medtronic Valve Device (DSMB) None None None Christine E. Seidman Howard Hughes Medical Institute; Harvard Medical School/Brigham and Women's Hospital—Investigator; T.W. Smith Professor of Medicine and Genetics None None None None None None None Jeffrey A. Towbin Cincinnati Children's Hospital—Executive Co-Director, The Heart Institute; Professor and Chief, Pediatric Cardiology None None None None None None None James E. Udelson Tufts Medical Center—Chief, Division of Cardiology None None None None None None None Clyde W. Yancy Baylor University Medical Center—Medical Director None None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. DSMB , Data safety monitoring board. ∗ Writing committee members are required to recuse themselves from voting on sections where their specific relationships with industry may apply. Section numbers apply to the full-text guideline. † No financial benefit. ‡ Significant relationship. Appendix 2. Appendix 2 Reviewer relationships with industry and other entities (Relevant)—2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy Peer reviewer Representation Consultant Speaker's bureau Ownership/ partnership/ principal Personal research Institutional, organizational, or other financial benefit Expert witness David R. Holmes, Jr Official Reviewer—ACCF Board of Governors/ACCF Interventional Scientific Council None None None None None None William J. McKenna Official Reviewer—AHA None None None None None None William G. Stevenson Official Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None None None None Carole A. Warnes Official Reviewer—ACCF Board of Trustees None None None None None None Michael Argenziano Organizational Reviewer—AATS None None None None None None Drew E. Baldwin Organizational Reviewer—SCAI None None None • Atrium † • GlaxoSmithWellcome † • Harvard Clinical Research Institute † • Greater New Orleans Health Services Corps * None Hugh Calkins Organizational Reviewer—HRS • Medtronic • Boston Scientific None • Boston Scientific * • Medtronic * • St. Jude Medical * None None Milind Y. Desai Organizational Reviewer—ASNC None None None None None None Vasken Dilsizian Organizational Reviewer—ASNC None None None None None None N.A. Mark Estes III Organizational Reviewer—HRS • Boston Scientific * None None None None None Michael Givertz Organizational Reviewer—HFSA None None None None None None Stuart Katz Organizational Reviewer—HFSA • Amgen • Bristol-Myers Squibb • Paracor • Terumo • Otsuka None None None None John A. Kern Organizational Reviewer—AATS None None None None None None Sherif Nagueh Organizational Reviewer—ASE None None None None None None Paul Sorajja Organizational Reviewer—SCAI None None None None None None Kirk T. Spencer Organizational Reviewer—ASE None None None None None None Gus J. Vlahakes Organizational Reviewer—STS None None None None None None Herbert B. Ward Organizational Reviewer—STS None None None None None None Nancy M. Albert Content Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None None None None Jeffrey L. Anderson Content Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None • AstraZeneca (DSMB) • Toshiba None None Richard G. Bach Content Reviewer None None None None None None Jorge A. Belardi Content Reviewer— ACCF Interventional Scientific Council • Boston Scientific • Medtronic CardioVascular • Medtronic Vascular • Abbott • Boston Scientific None None None None Eugene Braunwald Content Reviewer None None None None None None John E. Brush, Jr Content Reviewer • Prometheus Payment † • United Healthcare None None None None None James A. Burke Content Reviewer— ACCF Interventional Scientific Council None None None None None None Jose G. Diez Content Reviewer— ACCF Interventional Scientific Council • Sanofi-aventis Sanofi-aventis None None None None Jon C. George Content Reviewer— ACCF Interventional Scientific Council None None None None None None Robert A. Guyton Content Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None None None None Judith S. Hochman Content Reviewer—ACCF/AHA Task Force on Practice Guidelines • GlaxoSmithKline None None None None None Frederick G. Kushner Content Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None None None None Gilead I. Lancaster Content Reviewer—ACCF Board of Governors None None • Cardiogal None None None Bruce W. Lytle Content Reviewer None None None None None None Abeel A. Mangi Content Reviewer None None None None None None Gerard R. Martin Content Reviewer—ACCF Adult Congenital and Pediatric Cardiology Council None None None None None None Debabrata Mukherjee Content Reviewer— ACCF Interventional Scientific Council None None None None None None Joseph P. Murgo Content Reviewer None None None None None None Patrick T. O'Gara Content Reviewer None None None None None None E. Magnus Ohman Content Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None None None None John F. Robb Content Reviewer—ACCF Board of Governors None None None None None None George P. Rodgers Content Reviewer—ACCF Board of Governors None None None None None None Chris Semsarian Content Reviewer None None None None None None Richard J. Shemin Content Reviewer—ACCF Surgeons' Scientific Council • Edwards Lifesciences None None None None None Mark V. Sherrid Content Reviewer None • Boston Scientific • GeneDx • Medtronic • St. Jude Medical None • CardioNet None None William H. Spencer Content Reviewer None None Medtronic * None None None Paolo Spirito Content Reviewer None None None None None None Edward F. Terrien Content Reviewer—ACCF Board of Governors None None None None None None Juan Villafane Content Reviewer—ACCF Board of Governors None None None None None None Gary D. Webb Content Reviewer— ACCF Adult Congenital and Pediatric Cardiology Council None None None None None None Walter R. Wilson Content Reviewer None None None None None None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. AATS , American Association for Thoracic Surgery; ACCF , American College of Cardiology Foundation; AHA , American Heart Association; ASE, American Society of Echocardiography; ASNC, American Society of Nuclear Cardiology; DSMB , data safety monitoring board; HFSA , Heart Failure Society of America; HRS, Heart Rhythm Society; SCAI , Society for Cardiovascular Angiography and Interventions; and STS, Society of Thoracic Surgeons. ∗ Significant relationship. † No financial benefit. ",

year = "2011",

month = dec,

doi = "10.1016/j.jtcvs.2011.10.019",

language = "English (US)",

volume = "142",

pages = "1303--1338",

journal = "Journal of Thoracic and Cardiovascular Surgery",

issn = "0022-5223",

publisher = "Elsevier Inc.",

number = "6",

}

Gersh, BJ, Maron, BJ, Bonow, RO, Dearani, JA, Fifer, MA, Link, MS, Naidu, SS, Nishimura, RA, Ommen, SR, Rakowski, H, Seidman, CE, Towbin, JA, Udelson, JE, Yancy, CW, Jacobs, AK, Smith, SC, Anderson, JL, Albert, NM, Buller, CE, Creager, MA, Ettinger, SM, Guyton, RA, Halperin, JL, Hochman, JS, Krumholz, HM, Kushner, FG, Ohman, EM, Page, RL, Stevenson, WG & Tarkington, LG 2011, '2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary', Journal of Thoracic and Cardiovascular Surgery, vol. 142, no. 6, pp. 1303-1338. https://doi.org/10.1016/j.jtcvs.2011.10.019

TY - JOUR

T1 - 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy

T2 - Executive summary

AU - Gersh, Bernard J.

AU - Maron, Barry J.

AU - Bonow, Robert O.

AU - Dearani, Joseph A.

AU - Fifer, Michael A.

AU - Link, Mark S.

AU - Naidu, Srihari S.

AU - Nishimura, Rick A.

AU - Ommen, Steve R.

AU - Rakowski, Harry

AU - Seidman, Christine E.

AU - Towbin, Jeffrey A.

AU - Udelson, James E.

AU - Yancy, Clyde W.

AU - Jacobs, Alice K.

AU - Smith, Sidney C.

AU - Anderson, Jeffrey L.

AU - Albert, Nancy M.

AU - Buller, Christopher E.

AU - Creager, Mark A.

AU - Ettinger, Steven M.

AU - Guyton, Robert A.

AU - Halperin, Jonathan L.

AU - Hochman, Judith S.

AU - Krumholz, Harlan M.

AU - Kushner, Frederick G.

AU - Ohman, E. Magnus

AU - Page, Richard L.

AU - Stevenson, William G.

AU - Tarkington, Lynn G.

N1 - Funding Information: MMC4 Appendix 1. Appendix 1 Author relationships with industry and other entities (relevant)—2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy Committee member Employer/title Consultant Speaker's bureau Ownership/ partnership/ principal Personal research Institutional, organizational, or other financial benefit Expert witness Voting recusals by section number ∗ Bernard J. Gersh, Co-Chair Mayo Clinic—Professor of Medicine • Abbott Laboratories † • AstraZeneca • Boston Scientific • Bristol-Myers Squibb None None • Amorcyte (DSMB) • CV Therapeutics None 6.2.2.6 6.2.3 6.3.2 6.3.2.4 Barry J. Maron, Co-Chair Minneapolis Heart Institute Foundation—Director, Hypertrophic Cardiomyopathy Center • GeneDx ‡ None None • Medtronic ‡ None None 5.1 6.3.2 6.3.2.4 Robert O. Bonow Northwestern University Feinberg School of Medicine—Goldberg Distinguished Professor of Medicine; Chief, Division of Cardiology None None None None None None None Joseph A. Dearani Mayo Clinic—Professor of Surgery None None None None None None None Michael A. Fifer Massachusetts General Hospital—Director, Hypertrophic Cardiomyopathy Program None None None • Merck ‡ None None 6.2.1 Mark S. Link Tufts Medical Center—Professor of Medicine None • Medtronic • Guidant None • Guidant None • Plaintiff, wrongful death secondary electrocution, 2007–2009 • Defendant, postoperative valve replacement management, 2007–2010 6.2.2.6 6.3.2 6.3.2.4 Srihari S. Naidu Winthrop University Hospital—Director, Cardiac Catheterization Laboratory; Director, Hypertrophic Cardiomyopathy Center None • Abbott Vascular • Cordis • Medtronic None None None None 6.2.2.6 6.3.2 6.3.2.4 Rick A. Nishimura Mayo Clinic—Consultant in Cardiology None None None None None None None Steve R. Ommen Mayo Clinic—Professor of Medicine None None None None None None None Harry Rakowski Toronto General Hospital, University Health Network—Director, Hypertrophic Cardiomyopathy Center; Wigle Chair for HCM Research; Professor of Medicine, University of Toronto None None None • Medtronic Valve Device (DSMB) None None None Christine E. Seidman Howard Hughes Medical Institute; Harvard Medical School/Brigham and Women's Hospital—Investigator; T.W. Smith Professor of Medicine and Genetics None None None None None None None Jeffrey A. Towbin Cincinnati Children's Hospital—Executive Co-Director, The Heart Institute; Professor and Chief, Pediatric Cardiology None None None None None None None James E. Udelson Tufts Medical Center—Chief, Division of Cardiology None None None None None None None Clyde W. Yancy Baylor University Medical Center—Medical Director None None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. DSMB , Data safety monitoring board. ∗ Writing committee members are required to recuse themselves from voting on sections where their specific relationships with industry may apply. Section numbers apply to the full-text guideline. † No financial benefit. ‡ Significant relationship. Appendix 2. Appendix 2 Reviewer relationships with industry and other entities (Relevant)—2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy Peer reviewer Representation Consultant Speaker's bureau Ownership/ partnership/ principal Personal research Institutional, organizational, or other financial benefit Expert witness David R. Holmes, Jr Official Reviewer—ACCF Board of Governors/ACCF Interventional Scientific Council None None None None None None William J. McKenna Official Reviewer—AHA None None None None None None William G. Stevenson Official Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None None None None Carole A. Warnes Official Reviewer—ACCF Board of Trustees None None None None None None Michael Argenziano Organizational Reviewer—AATS None None None None None None Drew E. Baldwin Organizational Reviewer—SCAI None None None • Atrium † • GlaxoSmithWellcome † • Harvard Clinical Research Institute † • Greater New Orleans Health Services Corps * None Hugh Calkins Organizational Reviewer—HRS • Medtronic • Boston Scientific None • Boston Scientific * • Medtronic * • St. Jude Medical * None None Milind Y. Desai Organizational Reviewer—ASNC None None None None None None Vasken Dilsizian Organizational Reviewer—ASNC None None None None None None N.A. Mark Estes III Organizational Reviewer—HRS • Boston Scientific * None None None None None Michael Givertz Organizational Reviewer—HFSA None None None None None None Stuart Katz Organizational Reviewer—HFSA • Amgen • Bristol-Myers Squibb • Paracor • Terumo • Otsuka None None None None John A. Kern Organizational Reviewer—AATS None None None None None None Sherif Nagueh Organizational Reviewer—ASE None None None None None None Paul Sorajja Organizational Reviewer—SCAI None None None None None None Kirk T. Spencer Organizational Reviewer—ASE None None None None None None Gus J. Vlahakes Organizational Reviewer—STS None None None None None None Herbert B. Ward Organizational Reviewer—STS None None None None None None Nancy M. Albert Content Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None None None None Jeffrey L. Anderson Content Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None • AstraZeneca (DSMB) • Toshiba None None Richard G. Bach Content Reviewer None None None None None None Jorge A. Belardi Content Reviewer— ACCF Interventional Scientific Council • Boston Scientific • Medtronic CardioVascular • Medtronic Vascular • Abbott • Boston Scientific None None None None Eugene Braunwald Content Reviewer None None None None None None John E. Brush, Jr Content Reviewer • Prometheus Payment † • United Healthcare None None None None None James A. Burke Content Reviewer— ACCF Interventional Scientific Council None None None None None None Jose G. Diez Content Reviewer— ACCF Interventional Scientific Council • Sanofi-aventis Sanofi-aventis None None None None Jon C. George Content Reviewer— ACCF Interventional Scientific Council None None None None None None Robert A. Guyton Content Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None None None None Judith S. Hochman Content Reviewer—ACCF/AHA Task Force on Practice Guidelines • GlaxoSmithKline None None None None None Frederick G. Kushner Content Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None None None None Gilead I. Lancaster Content Reviewer—ACCF Board of Governors None None • Cardiogal None None None Bruce W. Lytle Content Reviewer None None None None None None Abeel A. Mangi Content Reviewer None None None None None None Gerard R. Martin Content Reviewer—ACCF Adult Congenital and Pediatric Cardiology Council None None None None None None Debabrata Mukherjee Content Reviewer— ACCF Interventional Scientific Council None None None None None None Joseph P. Murgo Content Reviewer None None None None None None Patrick T. O'Gara Content Reviewer None None None None None None E. Magnus Ohman Content Reviewer—ACCF/AHA Task Force on Practice Guidelines None None None None None None John F. Robb Content Reviewer—ACCF Board of Governors None None None None None None George P. Rodgers Content Reviewer—ACCF Board of Governors None None None None None None Chris Semsarian Content Reviewer None None None None None None Richard J. Shemin Content Reviewer—ACCF Surgeons' Scientific Council • Edwards Lifesciences None None None None None Mark V. Sherrid Content Reviewer None • Boston Scientific • GeneDx • Medtronic • St. Jude Medical None • CardioNet None None William H. Spencer Content Reviewer None None Medtronic * None None None Paolo Spirito Content Reviewer None None None None None None Edward F. Terrien Content Reviewer—ACCF Board of Governors None None None None None None Juan Villafane Content Reviewer—ACCF Board of Governors None None None None None None Gary D. Webb Content Reviewer— ACCF Adult Congenital and Pediatric Cardiology Council None None None None None None Walter R. Wilson Content Reviewer None None None None None None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. AATS , American Association for Thoracic Surgery; ACCF , American College of Cardiology Foundation; AHA , American Heart Association; ASE, American Society of Echocardiography; ASNC, American Society of Nuclear Cardiology; DSMB , data safety monitoring board; HFSA , Heart Failure Society of America; HRS, Heart Rhythm Society; SCAI , Society for Cardiovascular Angiography and Interventions; and STS, Society of Thoracic Surgeons. ∗ Significant relationship. † No financial benefit.

PY - 2011/12

Y1 - 2011/12

UR - http://www.scopus.com/inward/record.url?scp=81255163417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255163417&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2011.10.019

DO - 10.1016/j.jtcvs.2011.10.019

M3 - Article

C2 - 22093712

AN - SCOPUS:81255163417

SN - 0022-5223

VL - 142

SP - 1303

EP - 1338

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

IS - 6

ER -

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this